The global warm autoimmune hemolytic anemia (waiha) treatment industry is worth USD 638.96 Million in the year 2023 and is expected to reach USD 1598 Million by the year 2033 at a CAGR of 9.6% between 2023 and 2033.
Warm autoimmune hemolytic anemia (WAIHA) treatment implies medical interventions used for managing symptoms as well as underlying causes pertaining to WAIHA. In WAIHA, the immune system attacks as well as destroys red blood cells; thereby resulting in anemia. The treatment pertains to utilization of immunosuppressive drugs like corticosteroids. The other treatments could be inclusive of immunomodulatory drugs like cyclophosphamide or rituximab.
In certain cases, there could be blood transfusions used for replacing blood cells that have been destroyed. In case of severity, a splenectomy (removing the spleen surgically) could be essential for reducing red blood cells’ destruction.
The pharmaceuticals vertical is into adoption of novel treatments for the autoimmune diseases inclusive of WAIHA. On these grounds, the US FDA, in 2019, did approve Zilucoplan (brand name: Viltepso) to treat autoimmune hemolytic anemia.
At the same time, the fact that WAIHA treatments are costly can’t be ignored; especially for the ones who need prolonged therapy. This could make it tad difficult for certain patients to continue. Furthermore, the downtime needed on the whole is also more as diagnosis for WAIHA is made by combining laboratory tests, clinical evaluation, and imaging studies; which could be resulting in delays in treatment. These factors are likely to restrain the Warm Autoimmune Hemolytic Anemia (WAIHA) treatment industry in the near future.
Future Market Insights has walked through these facts with future prospects in its latest market study entitled ‘Warm Autoimmune Hemolytic Anemia (WAIHA) treatment industry. It has its team of analysts and consultants to see through a 360-degree approach in its primary, secondary, and tertiary modes of research.
“Call for reduction in destruction of red blood cells is expected to take the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment industry by storm in the forecast period”, says an analyst from Future Market Insights.
Key Takeaways from Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment industry:
- North America holds the largest market share due to the US being subject to advanced healthcare infrastructure along with an influx of skilled workforce.
- Europe holds the second-largest market share with growing advancements in healthcare vertical with novel diagnostic tools as well as treatment options.
- The Asia-Pacific is expected to grow at the quickest rate in the warm autoimmune hemolytic anemia (WAIHA) treatment industry with growing awareness regarding diagnosis of WAIHA.
Rising Interest in Market Trends: Our Detailed Report Provides Essential Insights!
Competitive Treatment:
- Johnson & Johnson is involved in developing a drug known as Uplizna (inebilizumab). It’s one of the humanized monoclonal antibodies targeting CD19 protein on the B cells. It is involved in activating the B cells, and dissecting CD19. The basic purpose is that of reducing production of the autoantibodies in ailments like WAIHA.
- Rigel Pharmaceuticals is into developing a drug known as Fostamatinib (better known as Tavalisse) to treat Warm Autoimmune Hemolytic Anemia (WAIHA). It’s an oral drug inhibiting SYK (spleen tyrosine kinase), an enzyme involved into a thing called ‘immune cell signaling’. Fostamatinib thus reduces destruction of the red blood cells; thereby exercising control over anemia.
What does the Report state?
- The research study is based on drug class (Fostamatinib, Sutimlimab, Parsaclisib, Rilzabrutinib, and Isatuximab), and by distribution channel (hospital pharmacies, online pharmacies, and retail pharmacies).
- Pharmaceuticals vertical is expected to be the cornerstone of warm autoimmune haemolytic anemia (WAIHA) treatment industry in the near future.
Key Companies Profiled:
- Rigel Pharmaceuticals
- Apellis Pharmaceuticals, Inc.
- Johnson & Johnson
- Sanofi
- Incyte Corporation
- Teva Pharmaceutical Industries Ltd
- Momenta Pharmaceuticals
- Alexion Pharmaceuticals, Inc.
- Immunovant
- F. Hoffmann-La Roche Ltd
Key Segments Profiled in the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry Survey
Drug Class:
- Fostamatinib
- Sutimlimab
- Parsaclisib
- Rilzabrutinib
- Isatuximab
Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
